The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder

Ibrahim, Nurul Khalida; Elzagheid, Adam; El-Hashmi, H.; Syrjänen, Kari; Alhakim, S.

doi:10.3402/ljm.v4i4.4839

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They reported that the commonest affected age of presentation of urothelial cell carcinoma of bladder is 50 to 70 years Bladder urothelial cell carcinoma revealed negative expression of p53 in 15 (37.5%) of high grade samples, and positive expression of p53 in 7 (17.5%) too. While 14 (35%) of low grade sample show negative expression of p53 and 4 (10%) show positive of p53 expression, concluded that there are no association between expression of p53 and grade of tumor show (p value=0.449), This result consist by Ibrahim et al [13]. Others against reported significant correlation with higher grades [14,15,16,17].…”

Section: Discussionmentioning

confidence: 77%

Immunohistochemical Expression of p53 Biomarker in Urinary Bladder Urothelial Carcinoma among Sudanese Patients

Hammed¹,

Adam²,

Elhussain³

2020

IJCEMR

View full text Add to dashboard Cite

Background: Urothelial (transitional cell) bladder carcinoma UBC is the most common malignancy of the urinary tract and the seventh leading cancer in men worldwide. Mutations in P53 gene are the most common genetic abnormality inhuman cancer. Mutation of P53 gene results P53protein accumulation in cells' nuclei. This accumulation is detectable with Immunohistochemical methods and correlates with P53 gene mutation. Aims: The study aimed to detect the expression of p53 in Urothelium cell carcinoma of urinary bladder using Immunohistochemical method, and correlate the expression of p53 with the gender, age of patient and histological grade. Methods: Forty paraffin embedded blocks previously diagnosed as transitional cell carcinoma were collected. This retrospective analytical study conducted at,

show abstract

Section: Discussionmentioning

confidence: 77%

Immunohistochemical Expression of p53 Biomarker in Urinary Bladder Urothelial Carcinoma among Sudanese Patients

Hammed¹,

Adam²,

Elhussain³

2020

IJCEMR

View full text Add to dashboard Cite

show abstract

“…In this study, though the frequency of p53 expression was higher for higher stage tumours, statistical significance was nil. But, this relation was proved by studies conducted by Ibrahim et al 14 and Galmozzi et al 15…”

Section: Discussionmentioning

confidence: 91%

A Study of P53 Expression in Urothelial Neoplasms of Urinary Bladder

G¹,

C.H²

2017

jebmh

View full text Add to dashboard Cite

BACKGROUND Urothelial Cell Carcinoma (UCC) of urinary bladder is the seventh commonest cancer wordwide. 1 At initial diagnosis, 30% of UCC display solid and invasive growth patterns and are locally advanced or metastatic at the time of diagnosis. 70% of tumours are noninvasive papillary UCC confined to the epithelium and subepithelial connective tissue, 2 which can be managed by endoscopic resection. A significant number of post-resected cases, progress for recurrence of tumour and infiltration to muscle layers. Invasive bladder cancer has high morbidity and uniform mortality when it is metastatic. There are no effective tools to predict aggressiveness of tumour, so that these cases can be managed more successfully. Mutated Tp53/p53 is the genetic abnormality most frequently associated with UCC and related to cell transformation, malignancy and high recurrence rates. 2 MATERIALS AND METHODS This is a descriptive study conducted in the departments of urology and pathology and during the period of March 2014 to February 2015. All consecutive cystoscopic biopsies, Trans urethral resection of bladder tumour (TURBT) and radical cystectomy specimens histopathologically diagnosed as UCC were included in the study. p53 expression was assessed by immunohistochemistry. Positive and negative controls were used. Bivariate analysis was done using Chi-square test in all cases. RESULTS A total of 80 cases were analysed. Significant association of p53 expression was found in higher grades of tumour. Also, noted relation of p53 mutation with tumour size, multifocality, multiplicity, muscle invasion and tumour stage, which were statistically not significant. CONCLUSION Bladder tumour grade shows significant association to p53 expression. Papillary neoplasm of low malignant potential (PUNLMP) tumours are negative for p53, and in the present study, there was significant difference in p53 over expression low-grade papillary UCC compared with PUNLMP. 90% of low-grade papillary tumours were p53 positive. This indicates a crucial role of p53 mutation in further tumour progression from PUNLMP to low-grade UCC. p53 mutation may have a role in transformation of low to high-grade TCC, and in this study, we found increased p53 expression with increased grade. But, though tumour size, multifocality, recurrent tumours and advanced stage show positive relation to p53, the association couldn't be proved to be statistically significant.

show abstract

Molecular Signatures in Urologic Tumors

Larkin

Kyprianou

2013

IJMS

View full text Add to dashboard Cite

Urologic tumors continue to represent a huge fraction of cancer cases in the United States, with over 376,310 estimated new diagnoses in 2013. As with many types of tumors, urologic tumors vary greatly in their phenotype, ranging from minimally invasive to malignancies possessing great metastatic potential. The increasing need for more efficient and less invasive methods of cancer detection, as well as the ability to predict severity of the disease phenotype is readily evident—yet reliable methods remain elusive in a clinical setting today. Comprehensive panels of gene clusters are being developed toward the generation of molecular signatures in order to better diagnose urologic malignancies, and identify effective treatment strategies in the emerging era of personalized medicine. In this review, we discuss the current literature on the credibility and biomarker value of such molecular signatures in the context of clinical significance relating to the pathological aggressiveness of urologic tumors (prostate, bladder and renal cancer)—also exploiting their predictive potential in the response to treatment.

show abstract

The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder

Cited by 3 publications

References 17 publications

Immunohistochemical Expression of p53 Biomarker in Urinary Bladder Urothelial Carcinoma among Sudanese Patients

Immunohistochemical Expression of p53 Biomarker in Urinary Bladder Urothelial Carcinoma among Sudanese Patients

A Study of P53 Expression in Urothelial Neoplasms of Urinary Bladder

Molecular Signatures in Urologic Tumors

Contact Info

Product

Resources

About